false
Catalog
The Liver Meeting 2019
Cirrhotic Cardiomyopathy
Cirrhotic Cardiomyopathy
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Menhao Itzi, an assistant professor at Vanderbilt University, discussed cirrhotic cardiomyopathy in a presentation. Cirrhotic cardiomyopathy is defined as cardiac muscle dysfunction in patients with cirrhosis without a known cardiac disease. The pathophysiology involves myocardial fibrosis, myocardial hypertrophy, and subendocardial edema. Dr. Itzi highlighted studies showing the development of myocardial fibrosis in cirrhotic patients, potentially due to hepatic and myocardial inflammation and oxidative stress. He also discussed how the new criteria for diagnosing cirrhotic cardiomyopathy include assessing ejection fraction and diastolic dysfunction. The impact of strain imaging, ejection fraction cutoffs, and diastolic dysfunction on patient outcomes post liver transplant were also addressed. Dr. Itzi stressed the importance of monitoring cardiac function post-transplant and considering interventions such as ACE inhibitors or ARBs if necessary. The session concluded with a panel discussion on various aspects of cirrhotic cardiomyopathy, including diagnostic challenges and nutritional interventions for patients with cirrhosis.
Asset Caption
Presenter: Manhal Izzy
Keywords
cirrhotic cardiomyopathy
Dr. Menhao Itzi
Vanderbilt University
cardiac muscle dysfunction
myocardial fibrosis
ejection fraction
diastolic dysfunction
×
Please select your language
1
English